complete or timely way using other methods. Equally, the conditions to be studied must have clear importance to the ophthalmological community for at least one of the three following reasons: firstly, they are significant for public health or health policy; secondly, their study has important direct implica tions for clinical practice; and, thirdly, they offer the opportunity to study fundamental disease mechan isms. These requirements are illustrated by the range of studies currently being facilitated by BOSU. A study of Acanthamoeba keratitis and its relation to soft contact lens wear is a timely examination that has direct relevance to public health and clinical practice. Similarly, a study of the incidence and causes of loss of vision in the non-amblyopic eye amongst individuals with unilateral amblyopia addresses topical, unanswered questions important to the debate about childhood vision screening. By contrast, a study of sympathetic ophthalmia provides a new opportunity to characterise and clarify pathogenesis in a representative range of cases. Finally, a study of retinopathy of prematurity, to determine incidence and outcomes in a national cohort of affected children, will also gather informa tion of importance to future provision of screening services for this disorder.
BOSU offers the ophthalmological community a new and effective medium for improving the study, thereby the understanding, and ultimately the management, of a variety of important but rare ophthalmic disorders. Everyone involved in clinical, basic scientific, or epidemiological research on such disorders is encouraged to consider this new service. The success of BOSU, and the studies it supports, depends on the continued interest and involvement of the reporting clinicians who, together with their patients, it ultimately serves. It is hoped that the 767 ophthalmological community will continue to sup port this initiative to enhance the research base of ophthalmology. 
HOW SHOULD ACTIVE TOXOPLASMIC RETINOCHOROIDITIS BE TREATED?
Despite a plethora of publications concerning Toxo plasma and toxoplasmosis, ! clinical diagnosis of the ocular disease remains subjective, and treatment largely empirical. This is due, at least in part, to a lack of consistent data pertaining to the host-parasite relationship within the human uveo-retinal tract, and particularly whether, in vivo, Toxoplasma is actually responsible for initiation and perpetuation of the ocular disease. Such knowledge is necessary if there is to be a rational approach to the medical therapy of ocular toxoplasmosis?
The Toxoplasma tissue cyst may be the major contributor to the ongoing pathogenetic process. Electron microscopy of animal ocular tissue with optimal fixation has revealed that intact tissue cysts in the retina are invariably located within viable cells in the ganglion cell and/or inner nuclear layers.3 Demise of the host cell liberates viable toxoplasms and other Toxoplasma antigens into the surrounding host tissue, to elicit a localised inflammatory event and, perhaps, permitting parasitisation of adjacent cells. Activated macrophages and other immune cells process the Toxoplasma antigen, 4 thus suppressing the infection. Medical intervention is usually neces sary, however, to reduce progression of inflamma tion, especially if the lesion is considered clinically to be sight-threatening. 5 Proposed chemotherapeutic strategies for toxo plasmic retinopathy, 6 including cases associated with pregnancy, neonates and the severely immunocom-promised? should ideally eliminate free forms of Toxoplasma prior to their re-invasion of host cells, as well as parasites enclosed within intact tissue cysts. Moreover, ocular disease should not be exacerbated as a consequence of drug intervention. The mainstay of toxoplasmic retinochoroiditis fherapeutics in all categories of patient has been the folate synthesis inhibitors, primarily pyrimethamine and sulphadia zine. These, and the protein biosynthesis inhibitor clindamycin, are effective against the extra-cystic form of Toxoplasma only.s Thus, on a theoretical basis at least, these drugs are effective in vivo only during a relatively short period directly after the onset of a clinically perceived inflammatory episode. Immediate treatment with such agents at the onset of symptoms thus represents a logical approach to chemotherapy. Such intervention could reduce the likelihood of re-invasion by Toxoplasma of other host cells and, in theory at least, both shorten the disease process and reduce the likelihood of sub sequent extension and recurrence, by eliminating extracellular parasites before they penetrate adjacent host cells.
It remains to be established whether these drugs remain effective after an inflammatory episode is established. Only one publication provides data on this: a prospective multicentre controlled trial of folate antagonists and clindamycin in the context of treatment of ocular toxoplasmosis? In this study use of the drugs did not result in benefits to the patient in terms of reducing duration or severity of the perceived inflammatory episode, but pyrimethamine may have reduced the area of focal scarring, an observation which could, however, have been due to chance. Furthermore, the trial was not randomised or masked, and these factors may have influenced the outcome. Rational treatment strategies, for both immunocompetent and immunocompromised indivi duals, thus remain to be established. A recent longitudinal studylO aimed at assessing the features of the eye disease in early congenital toxoplasmosis, suggests that active lesions may become quiescent with pyrimethamine and sulphadiazine therapy.
Ocular toxoplasmosis in individuals infected with human immunodeficiency viruses provides a singular challenge to the ophthalmologist. Pyrimethamine and sulphadiazine (and clindamycin) are again the mainstay of treatment in this high-risk groupP Individual resolutions have been recorded with other drugs such as tetracycline and spiramycin12 in patients with AIDS. Clearly, a rational approach to chemotherapy, such as is available for treatment of toxoplasmic encephalitis,13 would be beneficial in the ocular setting. Furthermore, the potential role of other anti-Toxoplasma drugs including azithromycin and other newer macrolides, and the hydroxy naphthoquinone, atovaquone, with or without con-EDITORIALS current corticosteroid therapy, requires to be evaluated.
Systemic corticosteroids are commonly used as part of the medical treatment of active episodes of toxoplasmic retinochoroiditis. 6 Steroid therapy was introduced into Toxoplasma therapeutics shortly after the observation that focal inflammation and scarring were associated with the infection. The rationale for steroid use in the setting of active toxoplasmic retinochoroiditis is in prevention or reduction of retinal tissue damage by the so-called innocent bystander mechanism. There is histological evidence to support this effect, but whether steroid use actually does yield any therapeutic benefit to the patient remains controversial, and clearly requires . further investigation. Pharmacological immunosup pression with corticosteroids can enhance the pro gression of a Toxoplasma infection in laboratory animals, with increased proliferation of the protozoa within host tissues.
Of particular relevance to the outcome of ocular toxoplasmosis is that at therapeutic concentrations glucocorticoids, including progesterone, can mark edly suppress the antimicrobial activity of macro phages, even though they do not necessarily inhibit macrophage activation by cytokines. For some intracellular microbes this effect can be reduced by interferon-gamma (IFN-'Y) . Although some cytokines (e.g. interleukin-6) may be associated with an increase in the inflammatory response to Toxo plasma,14 others (e.g. IFN -'Y, tumour necrosis fac tor-alpha, interleukin-2, interleukin-12) are important in resistance against Toxoplasma.1 5 The last produces this effect by, for example, stimulation of macrophages and/or natural killer cells. Thus there may be a therapeutic role for cytokines in patients with toxoplasmic encephalitis. Utilisation of cyto kines in the immunosuppressed, or in immunoprivi leged sites such as the eye, however, may prove impracticable, thus precluding their therapeutic use in ophthalmology. Reduction in IFN-'Y or tumour necrosis factor-alpha in mice with post-natally acquired ocular toxoplasmosis actually increased the number of ocular lesions and the severity of the inflammatory response. 1 6 Glucocorticoids can act as regulators of the immune response and can suppress the synthesis of, for example, IFN-'YY Moreover, CMI response components can be suppressed by glucocorticoids through the induction of lymphocytopenia and monocytopenia, and through interference with the early stages of proliferation and differentiation of the immune response. Direct cytotoxicity in a small subset of activated lymphocytes can permit gluco corticoids to impair CM!. These events can increase the risk for disseminated viral infections, such as is known to occur with varicella-zoster virus. Thus administration of high doses of corticosteroids can present a distinct hazard to a recipient, this being especially so with young children. A recent media report18 cites the use of prednisolone therapy in a child with ocular inflammation, who subsequently died from a fulminating varicella-zoster infection.
Although rarely undertaken nowadays, use of corticosteroids as monotherapy for treatment of active focal toxoplasmic retinochoroiditis shows that there is no unequivocal evidence of iatrogenic complications. 19 There is, however, a theoretical risk of uncontrolled replication of Toxoplasma in the retinae of some patients, and this could lead to exacerbation of the disease process. By down regulating the inflammatory response without pro viding appropriate anti-protozoal cover, corticoster oid mono therapy could further increase the risk of recurrence of the infection, since the parasitic burden and the number of parasitised cells may be greater than if appropriate chemotherapeutic agents are provided. There are a number of anecdotal reports describing fulminant ocular toxoplasmosis when corticosteroids have been administered in the absence of anti-Toxoplasma chemotherapy. Periocu lar use of corticosteroids is also contraindicated, since this increases the risk of exacerbation of Toxoplasma infection?O Consideration of how medical treatment of toxo plasmic retinochoroiditis should be rationalised must involve analysis of aspects relating to the cell biology of Toxoplasma21 and, more specifically, the mechanism(s) of interaction of candidate drugs which target organelles of the protozoan.22 Such an approach would include host immune effects, such as the possible role of nitric oxide in stage conversion from the endozoite (tachyzoite) to cystozoite (bradyzoite) form of the protozoan,23 as well as the phylogeny of Toxoplasma, which has suggested that the clonal lineage of pathogenic strains of the protozoan may have important implications for the development of drug treatments? 4 Ultimately, how ever, the benefits of basic science studies and potential therapeutic value of such treatments in the ocular setting can be established only from internationally agreed classifications for both diag nosis and degree of severity of the disease process, taken in combination with findings from a large scale, longitudinal, randomised and masked multi centre drug-treatment trial. 
